Market Spotlight: Opioid-Induced Constipation
Market Spotlight: Opioid-Induced Constipation
This Market Spotlight report covers the Opioid-Induced Constipation market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, probability of success, epidemiology data, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
This Market Spotlight report covers the Opioid-Induced Constipation drugs market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, probability of success, epidemiology data, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- The approved drugs in the opioid-induced constipation (OIC) treatment market predominantly target opioid receptors, with the exception of Amitiza, a type-2 chloride channel activator. All of the marketed drugs are administered via the oral route, with one product also being available in a subcutaneous formulation.
- The largest proportion of industry-sponsored drugs in active clinical development for OIC are in Phase II, with only one drug in Phase III.
- Therapies in mid-to-late-stage development for OIC target opioid receptors and guanylyl cyclase c receptor. These therapies are administered via the oral route.
- The overall likelihood of approval of a Phase I gastroenterology (non inflammatory bowel disease)-other asset is 21%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 9.8 years from Phase I to approval, compared to 9.6 years in the overall gastroenterology (non inflammatory bowel disease) space.
- There have been only three licensing agreements involving OIC drugs during 2015–20. The largest deal was the $30m exclusive license agreement signed in April 2019 between Shionogi and BioDelivery Sciences, pursuant to which BioDelivery Sciences gained full rights to commercialize Symproic tablets 0.2mg in the US for the treatment of OIC in adult patients with chronic noncancer pain, including patients with chronic pain related to prior cancer.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for OIC have been in the late phases of development, with 61% in Phase III–IV, and 39% in Phase I–II.
- Clinical trial activity in the OIC space is dominated by completed trials. Progenics Pharmaceuticals has the highest number of completed clinical trials for OIC, with 13 trials.
- Progenics Pharmaceuticals leads the industry sponsors with the highest overall number of clinical trials for OIC, followed by Pfizer.
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 Management of OIC with laxatives
8 Management of OIC with opioid antagonists
9 Management of OIC with Amitiza, a secretagogue chloride channel activator
10 OIC, Recent prevalence studies
10 OIC, Challenges
11 MARKETED DRUGS
13 PIPELINE DRUGS
17 RECENT EVENTS AND ANALYST OPINION
17 Symproic for OIC (June 19, 2019)
17 Symproic for OIC (April 11, 2019)
18 Symproic for OIC (April 10, 2019)
20 PROBABILITY OF SUCCESS
21 LICENSING AND ASSET ACQUISITION DEALS
21 Shionogi Licenses Partial EU Rights For Rizmoic To Molteni
21 BioDelivery Gains US Rights to Shionogi’s Symproic For OIC
22 Sandoz Strikes Shionogi Partnership as Part of Pain Play
22 Deals Shaping The Medical Industry, January 2019
23 PARENT PATENTS
24 REVENUE OPPORTUNITY
25 CLINICAL TRIAL LANDSCAPE
26 Sponsors by status
27 Sponsors by phase
29 Prescription information
LIST OF FIGURES
13 Figure 1: Overview of pipeline drugs for OIC in the US
13 Figure 2: Pipeline drugs for OIC, by company
14 Figure 3: Pipeline drugs for OIC, by drug type
14 Figure 4: Pipeline drugs for OIC, by classification
20 Figure 5: Probability of success in the OIC pipeline
21 Figure 6: Licensing and asset acquisition deals in OIC, 2015–20
23 Figure 7: Parent patents in OIC
25 Figure 8: Clinical trials in OIC
25 Figure 9: Top 10 drugs for clinical trials in OIC
26 Figure 10: Top 10 companies for clinical trials in OIC
27 Figure 11: OIC trials sponsors by status
28 Figure 12: OIC trials sponsors, by phase
LIST OF TABLES
12 Table 1: Marketed drugs for OIC
15 Table 2: Pipeline drugs for OIC in the US
17 Table 3: Symproic for OIC (June 19, 2019)
18 Table 4: Symproic for OIC (April 11, 2019)
19 Table 5: Symproic for OIC (April 10, 2019)
24 Table 6: Historical global sales, by drug ($m), 2014–18
24 Table 7: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email firstname.lastname@example.org for further help or assistance.